Neutra Life Sciences Expands Clinical Research Capabilities Through New Joint Venture Partnerships

Neutra Corp's subsidiary, Neutra Life Sciences, is making significant strides in the clinical research industry by announcing new joint venture partnerships. These partnerships, spanning podiatry, radiation oncology, and dermatology, mark a strategic expansion for the company. The new sites include Epic Foot & Ankle Centers (www.epicfootandankle.com), Aspire Hospital Cancer Centers (www.aspirehealthcorp.com), and Radiant Dermatology & Aesthetics Clinic (www.radiantdermtx.com), enhancing Neutra Life Sciences' multi-specialty platform.

This expansion allows Neutra Life Sciences to serve a broader patient population and meet the increasing demands in clinical research. By diversifying into more medical specialties, the company positions itself as a leader in providing integrated clinical research solutions. The move is expected to accelerate the development of innovative treatments across various therapeutic areas, benefiting Contract Research Organizations (CROs) and Sponsors alike.

Sydney Jim, President and CEO of Neutra Corp, emphasized the importance of this growth, stating, 'Our growth reflects the increasing demand for high-quality, integrated clinical research solutions. By aligning with established private practices and opening these new specialized sites, we are not only expanding our service offerings but also fostering innovation in patient care and research.'

In a strategic shift, Neutra Corp has decided to wind down its subsidiary in the Hemp-Based Cannabis entity, VIVIS Corporation, to focus on long-term growth in the life sciences sector. This decision underscores the company's commitment to advancing clinical research capabilities and expanding its presence in the healthcare and biotechnology landscape. Neutra Life Sciences continues to build a robust network of clinical research sites, aiming to improve health outcomes through cutting-edge collaboration.